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The T helper 17 (Th17) cell pathway has been linked by genome-wide association studies to multiple autoim-
mune diseases. Identification of the genetic causes of primary immunodeficiency diseases revealed that
Th17 cells are also critical in host immunity to mucocutaneous candida infections and Staphylococcus
aureus. Therapeutic interventions with inhibitors of the different components of the pathway such as inter-
leukin-12 (IL-12), IL-23, IL-17A, and IL-17RA have variably beneficial effects in psoriasis, Crohn’s disease,
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and multiple sclerosis.
Thus, whereas Th17 cells are protective against Candida albicans and to a lesser degree Staphylococcus
aureus, they are pathogenic in many autoimmune diseases. Here, we compare and contrast the effects of hu-
man genetic mutations of and therapeutic interventions targeted at Th17 cell molecules. We discuss that
although there are similarities when Th17 cell pathway molecules are modulated, each molecule has unique
non-Th17 cell features that lead to different functional outcomes.Introduction
Current understanding of the role of the adaptive immune system
in autoimmune disease pathogenesis has largely been based on
the work of Bob Coffman and Tim Mossman who first proposed
three decades ago the existence of two distinct T cell subsets: T
helper 1 (Th1) and Th2 cells, based on cytokine phenotype (Mos-
mann et al., 1986). Upon activation, naive T cells expand and
differentiate into effector T cell subsets, producing distinct
cytokines and mediating independent effector functions. An
over-exuberant response against self antigens of Th1 cells,
which produce interferon-g (IFN-g) and interleukin-2 (IL-2) and
help generate a cellular immune response to intracellular patho-
gens, was implicated in the induction of autoimmune diseases.
However, elimination of Th1 cells or Th1 cytokines did not pre-
vent development of autoimmunity. In fact, the loss of IFN-g or
p35 chain of IL-12, both of which induce Th1 cell responses,
made mice more susceptible to development of experimental
autoimmune encephalomyelitis (EAE), an autoimmune disease
of the central nervous system (CNS), and other autoimmune dis-
eases. This led to the notion that there must be another cell type,
other than Th1 cells, that is probably responsible for the induc-
tion of autoimmune disease.
Discovery of IL-23, which shares the p40 chain with IL-12,
indirectly led to discovery of Th17 cells (Figure 1). Pioneering
studies (Cua et al., 2003; Murphy et al., 2003) utilizing IL-12-
and IL-23-deficient mice demonstrated that it was loss of IL-
23 and not IL-12 that made mice resistant to the development
of EAE and collagen-induced arthritis (CIA). The mice deficient
in IL-23 lacked the expression of IL-17-producing T cells in the
target organ, which led to the suggestion that IL-23 might be
critical for the generation of pathogenic IL-17 producing
T cells, and loss of Th17 cells is responsible for the resistance
to autoimmune diseases in IL-23-deficient mice. However,
although IL-17-producing Th17 cells are indeed a novel subset1040 Immunity 43, December 15, 2015 ª2015 Elsevier Inc.of T cells, IL-23 alone is not responsible for their induction (dis-
cussed below).
Indeed, Th17 cells are potent inducers of tissue inflammation
and have been implicated in the pathogenesis of many ex-
perimental autoimmune diseases and human inflammatory
conditions. In fact, IL-17 and Th17 cells have shown to be
present at the tissue sites in a number of human autoimmune
diseases and have been implicated in the pathogenesis of rheu-
matoid arthritis, psoriasis, inflammatory bowel disease, and
Sjo¨gren’s syndrome. The primary function of Th17 cells, how-
ever, appears to be regulation of immune responses that
lead to the clearance of extracellular pathogens including
bacteria and fungi. In addition to inducing tissue inflammation,
Th17 cells have been shown to help B cells (Mitsdoerffer et al.,
2010) and play a critical role in forming ectopic lymphoid
follicles in the target organs (Ota et al., 2011; Peters et al.,
2011; Rangel-Moreno et al., 2011). The cytokines (IL-17, IL-22)
and cell-surface molecules (Podoplanin; also known as gp38)
selectively expressed by Th17 cells play a crucial role in orga-
nizing the formation of tertiary lymphoid follicle-like structures
in several different tissues including lung, gut, and the CNS of
the mice (Ota et al., 2011; Peters et al., 2011; Rangel-Moreno
et al., 2011).
IL-17 and IL-17R
Interleukin-17 (IL-17), the hallmark cytokine of Th17 cells, was
discovered in 1993 as a novel cytokine cloned from activated
cytotoxic T cells and named as CTLA8 (Rouvier et al., 1993).
Based on sequence homology, a total of sixmembers of the fam-
ily were discovered and called IL-17A, IL-17B, IL-17C, IL-17D,
IL-17E (also known as IL-25), and IL-17F. IL-17A is most closely
related to IL-17F, and both are produced by the same cells upon
activation. While IL-17A and IL-17F both can form homodimers,
they can also form heterodimers (IL-17A/F). Of all the family
IL-12Rβ2
IL-12Rβ1 IL-12Rβ1
IL-23R(β3)
p40 p35
Briakinumab
Ustekinumab
STAT3STAT4
Th17 differentiation
and expansion
Th1 differentiation
p40 p19
Guselkumab
Tildrakizumab
AMG 139
BI 655066
LY3074828
Figure 1. IL-12 and IL-23, Their Receptors,
and Key Molecules Involved in Signal
Transduction
IL-12 is a heterodimer of the IL-12+23 shared
subunit p40 (IL-12p40) and p35 (IL-12p35). IL-23
is a heterodimer of p40 (IL-12p40) and p19 (IL-
23p19). The IL-12R is a heterodimer composed of
the IL-12+23R shared chain IL-12Rb1 and IL-
12Rb2. IL-23R is a heterodimer of IL-12Rb1 and
IL-23R. STAT4 is involved in transducing signals
through IL-12R and STAT3 for IL-23R. Ustekinu-
mab and briakinumab bind IL-12p40 and block
the binding of both IL-12 and IL-23 to their re-
ceptors. Guselkumab, tildrakizumab, AMG 139,
LY3074828, and BI 655066 bind IL-23p19 and
block the binding of IL-23 to IL-23R.
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studied. IL-17 is produced not only by Th17 cells, but also by a
number of cell types including gd T cells, lymphoid tissue inducer
cells (LTi), innate lymphoid cells (ILCs), and natural killer (NK)
cells. IL-17A has also been reported to be produced by neutro-
phils (Ferretti et al., 2003; Taylor et al., 2014), but this is contro-
versial (Huppler et al., 2015). Thus, IL-17A is not identical to Th17
biology.
Soon after the discovery of IL-17 cytokine, the receptor for IL-
17 (Figure 2) was identified as a founding member of new family
of cytokine receptors (Gaffen, 2009). Based on sequence homol-
ogy, the IL-17 receptor family has now been identified to have 5
family members, including IL-17RA, IL-17RB, IL-17RC, IL-17RD,
and IL-17RE. IL-17RA is ubiquitously expressed on many non-
immune cells including epithelial and fibroblastic cells. In epithe-
lial and other parenchymal cells, IL-17R activation induces a
panel of proinflammatory cytokines including IL-1, IL-6, tumor
necrosis factor (TNF), MMPs, and IL-8 and thus making tissue
more amenable to cellular infiltration and tissue inflammation.
In addition to its expression on non-immune cells, recent studies
show that IL-17RA is also expressed on immune cells including
T cells where IL-17 signaling is considered to act as a positive
feedback loop and therefore further promote Th17 development
or function (Yosef et al., 2013).
IL-17A signals through a heterodimeric complex of IL-17RA
and IL-17RC to induce the required proinflammatory cytokine
production from responding cells. Like IL-17A, IL-17F also sig-
nals through IL-17RA-C but binds with 1%–10% of the affinity.
The functional outcome of IL-17A versus IL-17F binding to IL-
17 receptor has not been well studied.Immunity 43, DecWhile binding of IL-17A and IL-17F to
IL-17RA+IL-17RC and IL-17C to IL-
17RA+IL-17RE induces pro-inflamma-
tory cytokines and induces autoimmune
tissue inflammation, binding of IL-17E
to IL-17RA+RB induces Th2 cell-type re-
sponses, promotes allergic reactions,
and inhibits Th1 and Th17 cell biology.
The N-terminal end of the IL-17R has a
conserved SEFIR (similar expression of
fibroblast growth factor and IL-17R)
domain, which is closely related to TIR
domain expressed in TLR and IL-1Rfamily members (Gaffen, 2009). IL-17R signaling activates
SEFIR domain, which recruits ACT-1 (NF-kB activator 1) and ac-
tivates downstream NF-kB signaling via TRAF-6 (Wang et al.,
2013). Loss of ACT-1 or decoy peptides that block CC-domain
in the SEFIR domain also inhibit IL-17 dependent NF-kB
activation.
Differentiation of Th17 Cells
Th17 cells were initially characterized by the production of IL-
17A, but now have been shown to coproduce a group of cyto-
kines (IL-17A, IL-17F, IL-21, and IL-22), which coordinately act
to mediate tissue inflammation. Although initial studies sug-
gested that IL-23 is the differentiation factor for Th17 cells,
IL-23 cannot act on the naive T cells to induce Th17 cell differen-
tiation, and Kuchroo and Bettelli proposed that other factors
must be required to induce differentiation of naive T cells into
Th17 cell because naive T cells do not express IL-23R (Bettelli
and Kuchroo, 2005). Indeed, a series of studies showed that
Th17 cells differentiate from naive CD4+ T cells in response to
TGF-b plus IL-6 (Bettelli et al., 2006; Veldhoen et al., 2006;
Weaver et al., 2006) by inducing the expression of ROR-gt, a
master transcription factor required for the generation of Th17
cells. An emerging model for the development of Th17 cells in-
cludes three overlapping steps: differentiation, amplification,
and stabilization. TGF-b+IL-6 induces differentiation; IL-21 pro-
duced by developing Th17 cells mediates amplification; and
IL-23 expands and stabilizes previously differentiated Th17 cells.
In humans and mice, naive T cells can also be differentiated into
Th17 cells with IL-1+IL-6+IL-23, without any requirement for
TGF-b in the process (Ghoreschi et al., 2010), althoughember 15, 2015 ª2015 Elsevier Inc. 1041
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Figure 2. IL-17 Isoforms, Their Receptors,
and Key Molecules Involved in Signal
Transduction
All of the IL-17 isoforms exist as homodimers, but
IL-17A and IL-17F can also form a heterodimer,
IL-17A/F. Shown are the receptors for IL-17A, IL-
17C, IL-17E, and IL-17F. These receptors are
heterodimers of a signal transduction chain, IL-
17RA, and a chain that renders more specificity.
A heterodimer of IL-17RA and IL-17RC is the re-
ceptor for IL-17A, IL-17F, and IL-17A/F. A com-
plex of Act1, TRAF6, and TAK1 is involved in
transducing signals through IL-17R. Secukinu-
mab, ixekizumab, CNTO-6785, and CJM112 bind
IL-17A and block the binding of both IL-17A and
IL-17A/F to their receptor. Bimekizumab, ALX-
0761, and RG-7624 bind and neutralize both
IL-17A and IL-17F isoforms. Brodalumab binds
IL-17RA and blocks the binding of IL-17A, IL-
17A/F, IL-17F, IL-17C, and IL-17E to their
receptors.
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ferentiation cultures. These Th17 cells co-expressed both
RORgt and T-bet and were highly pathogenic in inducing exper-
imental autoimmune encephalomyelitis (EAE). The two types of
Th17 cells induced by TGF-b1+IL-6 or IL-1+IL-6+IL-23 appear
to be functionally and transcriptionally distinct, and might have
different roles in clearing different types of pathogens. Consis-
tent with this observation, in humans, two different types of
Th17 cells have also been described where Th17 cells that
produce IL-17 with IFN-g have specificity for Candida albicans
and in contrast the Th17 cells that coproduce IL-17 with IL-10
have specificity for Staphylococcus aureus (Zielinski et al.,
2012). Therefore, Th17 cells might come in different flavors,
with ability to clear different types of infections, and this might
also translate into whether some Th17 cells are highly patho-
genic and others are non-pathogenic in terms of inducing auto-
immune disease.
A number of studies have shown that a single nucleotide
polymorphism (SNP) in IL-23R is linked to human autoimmune
disease; raising the issue of whether IL-23R does something
more than just strengthening the phenotype of Th17 cells.
Whereas TGF-b+IL-6/IL-21 can induce Th17 differentiation,
exposure to IL-23 is critical for evoking pathogenic potential
in Th17 cells. Regulatory network analysis, based on protein-
protein networks suggests that IL-23 signaling induces SGK-
1, which promotes differentiation of pathogenic Th17 cells by
inducing phosphorylation of Foxo-1 and unabated expression1042 Immunity 43, December 15, 2015 ª2015 Elsevier Inc.of IL-23R and pathogenicity of Th17
cells (Wu et al., 2013). Transcriptomic
analyses have elucidated transcriptional
and regulatory networks that mediate
Th17 differentiation and function (Ciofani
et al., 2012; Wu et al., 2013; Yosef et al.,
2013). Th17 differentiation is accom-
plished in three different transcriptional
waves in 72 hr, and the major regulators
form two self-enforcing, mutually antag-
onistic modules that promote the differ-
entiation of Th17 cells and at the sametime inhibit differentiation of other T cell subsets (Yosef et al.,
2013).
Th17 Cells in Autoimmune Disease Models
It was initially believed that IFN-g producing Th1 cells, with
specificity for self-antigens are critical for the induction of auto-
immunity. This was based on the observation that Th1 cells pre-
dominate at the sites of tissue inflammation during autoimmune
disease. However, this concept was later refuted, because loss
of either IFN-g or cytokines (IL-12p35) or the receptors that drive
Th1 differentiation (IL-12Rb2) in mice were not resistant but
became more susceptible to multiple autoimmune diseases. In
sharp contrast, IL-12p40-deficient mice were resistant to multi-
ple autoimmune diseases. This problem was resolved when it
was discovered that the p40 chain can pair with another cytokine
chain called p19, forming a novel IL-23 heterodimer, and loss of
either p19 or p40 chain of IL-23 made mice resistant to multiple
autoimmune diseases including EAE, collagen-induced arthritis,
autoimmune colitis in IBD models, and experimental autoim-
mune uveitis. Consistent with these data, loss of IL-17A, IL-
17F, or their receptors, alone or in combination, made mice
resistant to the development of multiple autoimmune diseases
including EAE and CIA. Although IL-23 and IL-17A often have
similar effects in animal models of inflammation, they have
different effects in the gut. Loss or inhibition of IL-23 results in
protection from autoimmune colitis, but loss or inhibition of IL-
17A or IL-17RA in different models variably results in no
Immunity
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nor et al., 2009; Wang et al., 2015). Indeed, IL-17A might have a
protective effect by promoting and building epithelial barrier
functions (Lee et al., 2015). It should be emphasized that IL-23
does not only act on T cells but also gdT cells and ILCs to induce
IL-17 production and all these cells act in a coordinated fashion
to mediate autoimmune tissue inflammation, further highlighting
the idea that the various molecules and cells involved in the Th17
pathway might have distinct biological effects. These studies
highlight that Th17 cells are not the only source of IL-17 but
that other cell types including innate cells produce IL-17 and
therefore neutralizing IL-17 in vivo might be negating effects of
multiple cell types and not only of Th17 cells.
Th17 Cells and Human Disease
In addition to their role in inducing autoimmune disease in exper-
imental models, IL-17 and Th17 cells have been implicated in
multiple human autoimmune and infectious diseases. Th17 cells
infiltrate at a very high frequency in the affected joints in RA
patients and IL-17 activated osteoclasts can inducebone resorp-
tion and bone erosion (Miossec et al., 2009). IL-17 has been
identified in lesions inmultiple sclerosis, psoriasis, Sjo¨gren’s syn-
drome, and inflammatory bowel disease (Fujino et al., 2003;
Kotake et al., 1999; Lock et al., 2002; Teunissen et al., 1998). In
autoimmune diseases of the CNS, Th17 cells constitute the first
wave of pathogenic T cells infiltrating the CNS (Korn et al.,
2007), and thismight be related to their ability to efficiently breach
the blood-brain barrier (Kebir et al., 2007). Th17 cells might pro-
mote infiltration of other Th cells (like Th1 cells), macrophages,
and neutrophils, which further propagate tissue inflammation
and tissue damage. Furthermore, an unbiased whole-genome
transcriptomic analysis of the CNS of the MS patients showed
that IL-17 is the highest ranking gene expressed in the active pla-
que compared to the inactive plaques from the same patient
(Lock et al., 2002). Additional support for the role of Th17 cells
in inducing autoimmune diseases comes from genetic analysis
of human autoimmune diseases. A genome-wide association
scan for single nucleotide polymorphisms associated with hu-
man autoimmune diseases revealed that a specific coding
variant of the IL23R gene (arginine 381 to glutamine, R381Q, in
the cytoplasmic domain of IL-23R) conferred strong protection
from Crohn’s disease, whereas several variants in the non-cod-
ing region of this gene were associated with increased suscepti-
bility toCrohn’s disease (Duerr et al., 2006). R381Qhas nowbeen
shown to have a significant genetic association with multiple
other autoimmune diseases including psoriasis, psoriatic
arthritis, Crohn’s disease, rheumatoid arthritis, and ankylosing
spondylitis (AS) (Duerr et al., 2006; Farago´ et al., 2008; Hu¨ffmeier
et al., 2009; Liu et al., 2008; Rahman et al., 2008). However, the
mechanism by which this coding variant of IL-23R regulates
autoimmunity has not yet been elucidated.
Identification, largely by reverse genetics, of mutations of
components of the Th17 pathway has revealed an essential
role for Th17 immunity in protection against certain types of
fungal and bacterial infections, with a recurring theme that the ef-
fected individuals develop unrelenting chronic mucocutaneous
candidiasis (CMC) infections (Table 1). Mutations in IL-12Rb1,
the signal transduction chain of both IL-12 and IL-23 receptors
affecting both Th1 and Th17, leads to susceptibility to mycobac-teria, candidia, klebsiella, nocardia, and salmonella infections
(de Beaucoudrey et al., 2008; de Beaucoudrey et al., 2010;
Prando et al., 2013). Similarly, mutations in retinoic acid receptor
related orphan receptor C (RORC), the human version of mouse
RORg (not only gT), which regulates not only Th17 development
but also IFN-g production by several cell types, leads to impaired
immunity to Candida and mycobacteria (Okada et al., 2015).
Multiple different mutations in STAT-3, which cause auto-
somal-dominant hyper immunoglobulin E (IgE) syndrome, lead
to recurrent infections with Staphylococcus aureus and Candida
albicans. The mutations in the DNA binding, SRC homology, and
transactivating domains of STAT-3 result in almost complete
loss of Th17 differentiation, supporting the crucial role of
STAT-3 in Th17 differentiation and underscoring the value of
Th17 immunity in clearing fungal infections (Al Khatib et al.,
2009; de Beaucoudrey et al., 2008; Ma et al., 2008; Milner
et al., 2008), albeit the role of hypomorphic STAT-3 signaling in
stromal cells remains to be determined. A gain of function muta-
tion in the STAT-1 coil-coil domain resulted in skewing toward
Th1 away from Th17, and these patients also develop CMC
infection (Liu et al., 2011). Because Th17 cells are critical for
development of anti-fungal immunity, it was found that the hy-
phal form of Candida albicans and its derivatives (Zymosan
and b-glucan), both of which are Dectin-1 agonists, induced
IL-23 from human DCs. Consistent with this observation, pa-
tients with a stop-codon mutation (Tyr238X) in dectin-1 were
found to have a defect in the production of IL-17 and Th17 cells
and developed CMC (Carvalho et al., 2012; Plantinga et al.,
2009). Similarly, CMC is the primary infection observed in the pa-
tients with autoimmune polyendocrinopathy syndrome-1, and
these patients were observed to have circulating neutralizing an-
tibodies against IL-17A, IL-17F, and IL-22 (Kisand et al., 2010;
Puel et al., 2010). Patients with CMC have been found to have
defects in IL-17F and IL-17RA, but not in IL-17A, indicating
that IL-17F or IL-17A/F is important in protecting against CMC
(Puel et al., 2011). The CMC associated with IL-17RA deficiency
is complete, and that with IL-17F is partial, indicating that IL-17A
and IL-17F are essential but partially redundant for immunity
againstCandida albicans. Downstream of the IL-17 receptor, de-
fects in the signal transduction molecule Act1, which is primary
for IL-17R signaling but also modulates other receptors such
as CD40L and BAFFR, results in not only CMC but also in staph-
ylococcal infections (Boisson et al., 2013). Collectively, these
data suggest that Th17 cells have a critical role in immunity to
mucocutaneous Candida albicans and Staphylococcus aureus.
Therapeutic Interventions in Psoriasis
Rather than an historical perspective, we will take a pathways
approach to deciphering what therapeutic interventions in the
Th17 pathway have taught us about human immunology and dis-
ease, focusing on psoriasis as a model autoimmune disease and
then expanding on the roles of IL-17A and Th17 in other diseases
where the immune system has strong effects. While generaliza-
tions can be drawn about an important role for Th17 in the path-
ogenesis of various autoimmune diseases, one fundamental
finding is that each component of the Th17 pathway has different
effects, be they subtle or significant.
Of the molecules involved in human Th17 differentiation and
expansion, STAT3, IL-23, IL-23R, and RORC2 have relativeImmunity 43, December 15, 2015 ª2015 Elsevier Inc. 1043
Table 1. Genetic Defects in the Th17 Pathway Leading to Primary Immunodeficiency Diseases
Genea Inheritanceb Protein WT (mut.)c Domaind Regulation Infection risk Diseasee Reference
ACT1 ACT-1 (T536I) SEFIR Th17, impairs the
fibroblast response
to IL-17
Candida albicans,
Staphylococcus aureus
CMC (Boisson et al., 2013)
AIRE AR (G228W =
AD)
AIRE (G228W), >
50 others
DNABD and/or
multimerization
domain SAND
Neutralizing
autoantibodies against
IL-17A, IL-17F, IL-22
Candida albicans,
Staphylococcus aureus
CMC, APS-1/APECED/Whitaker
syndrome, hypoparathyroidism,
adrenocortical failure, dental
enamel dysplasia, nail
dystrophy, alopecia, ovarian
failure, vitiligo, diabetes mellitus,
testicular failure, hypothyroidism
(Bjo¨rses et al., 2000)
CARD9 AR CARD (G72S,
R373P)
CARD and coiled-coil Th17 differentiation Candida dubliniensis Meningoencephalitis,
mucocutaeneous candidiasis,
AS, CD, UC
(Drewniak et al., 2013)
DECTIN1 DECTIN-1 (Y238X) Carbohydrate
recognition
Th17 Candida albicans CMC (Carvalho et al., 2012;
Plantinga et al., 2009)
IL12B AR IL-12R, 9 mutations Signal transduction
chain
Reduction of Th1,
Th17 cells
Mycobacteria, candidia,
klebsiella, nocardia,
salmonella
MSMD, Bacille Calmette-Gue´rin
disease
(Prando et al., 2013)
IL12RB1 AR IL-12Rb1, > 100
mutations
Peptide leader
sequence, extracellular,
transmembrane, intra-
cellular cytoplasmic
Reduction of Th1,
Th17 cells
Mycobacteria, candidia,
klebsiella, nocardia,
salmonella
MSMD, Bacille Calmette-Gue´rin
disease
(de Beaucoudrey
et al., 2010; Ouederni
et al., 2014)
IL17F AD IL-17F (S65L) cytokine-to-receptor
binding
Blocks IL17F and
IL17A/F signaling
Candida albicans,
Staphylococcus aureus
CMC (Puel et al., 2011)
IL17RA AR IL-17RA (Q284X) Truncation in
extracellular domain
Loss of IL-17R
function
Candida albicans,
Staphylococcus aureus
CMC (Puel et al., 2011)
IL17RC IL-17RC Loss of IL-17RC
function
Candida albicans,
Staphylococcus aureus
CMC (Ma et al., 2008)
STAT1 STAT-1 Coil-coil domain Th17 cell reduction Candida albicans CMC (Liu et al., 2011; van de
Veerdonk et al., 2011)
STAT3 AD STAT-3 (V432M),
(R382Q), (H437P),
(Q644P)
DNABD, SH2,
transactivation domain
Th17 differentiation,
heterozygous loss-of-
function mutation
Staphylococcus aureus,
Candida albicans, fungal
infections, viral infections
Autosomal-dominant hyper IgE
syndrome (HIES) or Job’s
syndrome
(Ma et al., 2008;
Plantinga et al., 2009)
TYK2 AR TYK-2 Loss of IL-23 signaling,
Th17 maintenance
Staphylococcus aureus,
Candida albicans
Autosomal-dominant hyper IgE
syndrome (Job’s syndrome)
(Minegishi et al., 2006)
Abbreviations are as follows: RA, rheumatoid arthritis; CD, Crohn’s disease; BD, Behcet’s disease.
aACT1, Actin 1 gene; AIRE, autoimmune regulator; CARD9, caspase recruitment domain-containing protein 9; DECTIN1, dendritic-cell-associated C-type lectin-1.
bAD, autosomal dominant; AR, autosomal recessive.
cSTAT, signal transducer and activator of transcription; mAb, monoclonal antibody; LMW, Low molecular weight compound.
dSEFIR, similar expression to fibroblasts growth factor and IL-17R; SAND, Sp100, AIRE, NucP41/75, and DEAF-1; DNABD, DNA binding domain; SH2, src homology 2 domain.
eCMC, Chronic mucocutaeneous candidiasis; signal transducer and activator of transcription; APS-1, Autoimmune polyendocrine syndrome type 1; APECED, autoimmune polyendocrinopathy
candidiasis ectodermal dystrophy, UC, ulcerative colitis; MSMD, mendelian susceptibility to mycobacterial disease.
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Reviewspecificity for Th17 compared to other immunological pathways
and are potentially suitable for therapeutic intervention. Thus far,
there have been no STAT3- or IL-23R-specific therapeutic
interventions.
Two antibodies to IL-12p40 (ustekinumab and briakinumab),
which neutralize both IL-12 and IL-23 and have effects on both
Th1 and Th17 as well as other cell types expressing the IL-12
and IL-23 receptors, have been widely studied (Figure 1). Both
have shown good efficacy in psoriasis (Gordon et al., 2012; Kim-
ball et al., 2008; Leonardi et al., 2008; Papp et al., 2008), with
approximately 75% of patients achieving a 75% reduction in
thepsoriasis activity and severity index (PASI 75).While ustekinu-
mab is registered and available for use, large clinical studies with
briakinumab had an imbalance of major adverse cardiac events
(MACE) that led to its discontinuation (Gordon et al., 2012). The
reasonwhy briakinumab and not ustekinumab hadMACE events
is not clear because they both specifically target the same mole-
cule. However, data regarding levels of pathway inhibition of the
two antibodies are sparse. Post-marketing surveillance studies
have revealed no significant effects of ustekinumab on MACE
or non-NMSC (non-melanoma skin cancer) malignancies (Papp
et al., 2015). Although there have been reports of NMSC with us-
tekinumab use, the significance is not yet clear. Similar to many
immunologic interventions, there is a slight increase in infections
but no increase in the rate of serious infections compared to pla-
cebo. These clinical results suggest that the Th1 and/or Th17
pathways are important for the pathogenesis of psoriasis.
Studies with the p19 subunit of IL-23 (IL-23p19), which is more
specific than IL-12p40 for Th17 differentiation and expansion,
have provided the mechanistic insight that Th17 is the relevant
pathway for psoriasis. Several anti-IL-23p19 mAbs (guselkumab,
tildrakizumab,BI-655066,AMG139, andLY3074828) are currently
in clinical testing. Results from Phase 2 (early clinical studies with
limited numbers of patients) have shown excellent efficacy in pso-
riasis (Gordon et al., 2015; Kopp et al., 2015; Krueger et al., 2015).
Although it isearly inclinical testing, the resultsareonlywith limited
numbers of patients, and the dosing regimens of anti-IL23p19
mAbs have not yet been optimized, there appears to be better
efficacy in psoriasis by inhibiting IL-23 alone versus both IL-12
and IL-23. If confirmed, this would suggest that Th1 and Th17
are counterregulatory. The results of a recently completed head
to head study of BI-655066 with ustekinumab (ClinicaltTrials.gov
Identifier NCT02054481) are eagerly awaited. Thus, the Th17
pathway is important for the pathogenesis of psoriasis.
Currently, two low molecular weight oral compounds (VTP-
43472 and JTE-151) targeting the Th17 master regulator
RORC2 are in Ph1 trials in healthy volunteers. Although prelimi-
nary data indicate that VTP-43472 suppresses IL-17A produc-
tion in ex vivo stimulation studies under conditions promoting
Th17 development, little other information is available. Because
such compounds will target both RORC variants 1 and 2 (RORg
and RORgt in rodents) and are not specific for only RORC2, data
on their effects on various immune and non-immune pathways
are eagerly awaited. Thus far, the data in humans point to a
similar role for RORC as in rodents, albeit longer term and
more detailed data on larger numbers of treated patients and
long-term carcinogenicity studies in rodents will be needed to
understand the differences between pharmacologic inhibition
and genetic deficiency and whether thymic lymphomas willoccur with prolonged RORC suppression as they dowith genetic
RORg deficiency in rodents (Jetten, 2009).
Although IL-17A is the hallmark cytokine of Th17 cells, they
also produce IL-17F and IL-22, and all three cytokines have
been hypothesized in animal models to be effector cytokines
leading both to protection from infections and damage in autoim-
munity. Clinical studies targeting these cytokines or their recep-
tors are providing numerous data suggesting that IL-17A is a
primary effector cytokine leading to the clinical manifestations
of most but not all autoimmune diseases where Th17 has a role.
Listed in Table 2 are nine known molecules that target either
IL-17A or IL-17A+IL-17F that are being or have been clinically
tested (Figure 2). Although there are subtle differences between
these molecules in parameters such as immunogenicity, po-
tency, pharmacokinetics, dosing regimens, and side effect pro-
files, the findings and their implications for the understanding of
human immunology are quite similar. Thus, we will focus on the
one molecule where the first and most data exist (secukinumab)
and supplement with data from ixekizumab for confirmation.
Large Phase 3 clinical studies with both secukinumab and ixeki-
zumab have shown a remarkable efficacy of IL-17A inhibition in
psoriasis with 90% of patients achieving a PASI 75 and 40%
achieving a PASI 100 response with complete clearing of skin le-
sions (Griffiths et al., 2015; Langley et al., 2014; Thac¸i et al.,
2015). Indeed, head-to-head studies of secukinumab with uste-
kinumab showed significantly higher efficacy of IL-17A inhibition
compared to IL-12+23 blockade (see below). In smaller studies
evaluating disease pathogenesis by histologic and molecular
analysis, IL-17A inhibition results not only in improvements in
keratinocyte hyperplasia and acanthosis by blocking IL-17A ef-
fects on skin stromal cells, but also a dramatic reduction in
skin Th17 cells themselves, their products including IL-17A, IL-
17F, IL-21, and IL-22, and factors that drive Th17 including IL-
23, thus leading to the hypothesis that IL-17A augments a
positive feedback loop for Th17 cells (Hueber et al., 2010).
Although there were no cases of CMC, low rates of mild to mod-
erate candida infections that resolved on their own or with
standard therapy were seen with both secukinumab and usteki-
numab (Griffiths et al., 2015; Langley et al., 2014; Thac¸i et al.,
2015). No cases of tuberculosis reactivation were reported.
These data support the notion that IL-17A is a primary effector
cytokine of and critical intervention point for Th17 cells.
Whether inhibiting other familymembersof IL-17will have addi-
tional therapeuticbenefitor sideeffects is being testedbybiologic
agents that target both IL-17A and IL-17F (RG7624, ALX-0761,
and bimekizumab) and that target IL-17RA (brodalumumab).
Data are available only for brodalumumab, which has shown
excellent efficacy in psoriasis at the same levels as has been
seen with secukinumab (Lebwohl et al., 2015). As with targeting
IL-17A, mild to moderate candida infections were seen more
frequently with brodalumab than placebo. Although there are no
mechanistic explanations, and there might not be a causal rela-
tionship, brodalumab has been associated with suicidal ideation.
Otherwise, there do not appear to be major differences between
targeting IL-17A versus multiple IL-17 isoforms in psoriasis.
Targeting of IL-17A or IL-17RA appears to have better effects
than targeting IL-12+23. Although it is difficult to compare results
from different studies due to study design, patient selection, and
other variables, there have been three studies that comparedImmunity 43, December 15, 2015 ª2015 Elsevier Inc. 1045
Table 2. Therapeutic Interventions Affecting the Th17 Pathway
Target Agent Company Phasea Typeb Diseasesc
IL-17A Secukinumab (Cosentyx) Novartis Marketed Fully human mAb Pso, PsA, AS, MS,
Asthma, RA, Uveitis
IL-17A Ixekizumab Eli Lilly Phase 3 Humanized mAb Pso, PsA, RA
IL-17A CNTO-6785 Johnson & Johnson Phase 2 Fully human mAb RA, COPD
IL-17A CJM112 Novartis Phase 2 mAb Pso, HS
IL-17A SCH-900117 Merck Discontinued Fully human mAb RA
IL-17A RG-4934 Roche Discontinued Fully human mAb PsA, RA
IL-17A + IL-17F Bimekizumab UCB Phase 2 Humanized mAb Pso, PsA, RA
IL-17A + IL-17F RG7624, NI-1401 Roche Phase 1 Fully human mAb AID
IL-17A + IL-17F ALX-0761 Merck Serono, Ablynx Phase 1 Bispecific half-life-
extended nanobody
Pso
IL-17A + TNF-a COVA322 Johnson & Johnson Phase 2 Bispecific antibody
fusion protein
Pso, PsA, AS, RA
IL-17A + TNF-a ABT-122 AbbVie Phase 2 Dual-variable-domain
immunoglobulin
RA, PsA
IL-17A + TNF-a ABBV-257 AbbVie Phase 1 Dual-variable-domain
immunoglobulin
RA
IL-17RA Brodalumab, AMG 827 Amgen, AstraZeneca Phase 3 Fully human mAb Pso, PsA, Asthma
IL-22 Fezakinumab ILV-094 Pfizer Discontinued Fully human mAb Pso, RA
IL-23p19 Guselkumab CNTO-1959 Johnson & Johnson Phase 3 Fully human mAb Pso, PsA, RA, PP
IL-23p19 Tildrakizumab, SCH-
900222, MK-3222
Merck, Sun Pharma Phase 3 Fully human mAb Pso
IL-23p19 BI-655066 Boehringer Ingelheim Phase 2 Humanized mAb AS, CD, Pso, Asthma
IL-23p19 AMG 139, MEDI2070 Amgen, AstraZeneca Phase 2 Fully human mAb Pso, CD
IL-23p19 LY3074828 Eli Lilly Phase 1 Humanized mAb Pso
IL-12p40 + IL-23p40 Ustekinumab (Stelara) Johnson & Johnson Marketed Fully human mAb Pso, PsA, RA, CD
IL-12p40 + IL-23p40 Briakinumab, ABT-874 Abbott Discontinued Fully human mAb Pso
RORC VTP-43472 Vitae Pharmaceuticals Phase 1 LMW Pso, MS, RA, BD, Uveitis
RORC JTE-151 Japan Tobacco Phase 1 LMW Allergy, AID
aPhase 1 studies are generally for testing the safety and tolerability of new compounds in healthy subjects; Phase 2 studies are early studies that
test efficacy and safety on small numbers of patients; Phase 3 studies test efficacy and safety in large number of patients with an aim to gain market
authorization.
bmAb, monoclonal antibody; LMW, low molecular weight compound pulmonary disease.
cRegulatory authorities have approved use for underlined indications in one or more parts of the world; PP, Palmoplantar pustulosis; Pso, psoriasis;
PsA, psoriatic arthritis.
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study, 44% (148/334) of patients treated with secukinumab
versus 28% (95/335) of patients treated with ustekinumab
achieved PASI 100 responses (Thac¸i et al., 2015). In the
AMAGINE 2 and 3 studies, 44% (272/612) and 37% (229/624) of
patients treated with brodalumumab versus 22% (65/300) and
19% (58/313) of ustekinumab treated patients achieved PASI
100 (Lebwohl et al., 2015). Of the early clinical studies performed
with anti-IL23p19 mAbs, the best interpretable data to date are
withguselkumab,whichshowedanup to33%PASI100 response
rate (14/42 patients) after 16 weeks of treatment (Gordon et al.,
2015). It remains to be seen in larger Phase 3 and head-to-head
studies whether inhibiting IL-23 will be as efficacious as inhibiting
IL-17 or whether it will be closer to inhibiting IL-12+23.
Antibodies to IL-22 have also been tested in psoriasis. While
IL-22 is an effector cytokine produced by Th17 cells, it is also
the hallmark cytokine for Th22 cells that do not produce IL-17
and have the aryl hydrocarbon receptor (versus RORC) as their1046 Immunity 43, December 15, 2015 ª2015 Elsevier Inc.master regulator. A study with fezakinumab in psoriasis was
completed in 2010 (NCT00563524) with no final data released
and no further development reported, although an investigator-
initiated trial in atopic dermatitis is ongoing (NCT01941537).
The data are consistent with the hypothesis that Th1 and Th17
are counterregulatory, and that IL-17A is a primary effector cyto-
kine of Th17 cells, but the caveat remains that IL-17A is not the
only effector cytokine produced by Th17 cells and that it is
also produced by other cell types.
Th17 Pathway in Other Autoimmune Diseases
IL-17 and Th17 have been implicated in a multitude of diseases
other than psoriasis, and clinical trials with pathway inhibitors
have revealed results that were both expected and unexpected
from the previous knowledge (Table 3).
Crohn’s disease has strong genetic associations with Th17 by
virtue of SNPs in IL23R. Thus, it is not surprising that IL-12+23
blockade with ustekinumab had some beneficial effects in the
Table 3. Clinical Efficacy of Th17 Pathway Modulators
Disease (severity) IL-12+23 IL-23 IL-17A IL-17RA
Psoriasis ++ +++ +++ +++
Psoriatic Arthritis + n.t. ++ +
Ankylosing Spondylitis + n.t. ++ n.t.
Asthma n.t. n.t. n.a. -/+
Crohn’s disease ++ n.a.  
Multiple Sclerosis  n.t. ++ n.t.
Rheumatoid Arthritis +  ++ 
Uveitis (non-infectious) n.t. n.t. + n.t.
n.t., not tested; n.a., data not yet available; , not effective; +, partially
effective; ++, effective; +++, highly effective.
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TNF-a (Sandborn et al., 2012). A trial testing anti-IL-23p19
mAbs BI-655066 (NCT02031276) is ongoing with results avail-
able soon, and one with MEDI2070 (NCT02574637) is planned.
With the pathway association and efficacy of ustekinumab, it
was expected that IL-17 blockade would also be effective for
Crohn’s. However, anti-IL-17A mAb secukinumab was ineffec-
tive in moderate to severe Crohn’s disease (Hueber et al.,
2012), and development of brodalumab was also terminated
due to lack of efficacy in Crohn’s (Mozaffari et al., 2015). It might
be that IL-17A has a protective role in gut inflammation, and Th17
cells manifest their gut proinflammatory effects via other factors.
One of the earliest biologic activities of IL-17A and links to
inflammation were documented in synoviocytes from patients
with rheumatoid arthritis (Miossec and Kolls, 2012), and multiple
clinical studies have been performed testing different Th17
pathway inhibitors in RA. IL-17A inhibition with secukinumab re-
sulted in modest efficacy in RA patients who had inadequate re-
sponses to methotrexate with 54% achieving ACR20 (Felson
and LaValley, 2014) and 17% ACR50 responses at week 16
compared with placebo responses of 36% ACR20 and 6%
ACR50 (Genovese et al., 2013; Hueber et al., 2010). Similar re-
sults were obtained with ixekizumab where there was also mod-
erate efficacy in patients who were inadequate responders to
anti-TNF-a therapy (Genovese et al., 2014). Although the data
indicate an important biologic role for IL-17A in RA, the efficacy
was not considered robust enough to continue clinical develop-
ment toward registration and both programs have been stopped.
The hypothesis that dual inhibition of TNF-a with IL-17 might be
more beneficial than either alone is currently being tested with
three mAbs (COVA322, ABT-122, and ABBV-257). This combi-
nation is likely to be highly effective, and it remains to be seen
whether candida or other infections will limit the utility of the
combination. Interestingly, blockade of IL-17RA with brodalu-
mab at doses that have been effective in other diseases clearly
had no effect in RA patients with inadequate response to meth-
otrexate (Pavelka et al., 2015). These data raise important ques-
tions about differential regulation of synovial inflammation by the
different IL-17 family members. While IL-17A appears to be
proinflammatory in synovium, it is possible that IL-17E (also
known as IL-25), which has a role in Th2 responses and a protec-
tive effect in EAE, might have a counterregulatory effect in syno-
vial inflammation. A head-to-head study comparing IL-12+23
mAb ustekinumab with IL-23 mAb guselkumab in patients whowere MTX inadequate responders showed mild efficacy of
ustekinumab with ACR20 responses of 55% at week 28
versus 40% for placebo, but no efficacy for guselkumab with
ACR20 responses of 38% and 44% at two different doses
(NCT01645280). Thus, in the joint inflammation of RA, IL-17A ap-
pears to have a pathogenic role, but other Th17 derived cyto-
kines or IL-17 family members such as IL-17E might have a
protective role.
Enthesitis, inflammation at the sites of attachment of tendons
or ligaments to bone, is an IL-23 driven process that is pathogno-
monic for the seronegative spondyloarthropathies, psoriatic
arthritis (PsA), and AS (Ritchlin et al., 2014; Sherlock et al.,
2012). Indeed, blocking IL-12+23with ustekinumab for 24 weeks
showed overall ACR20 and ACR50 responses of 44% and 20%
compared to responses of 20% and 7% with placebo, and
ACR20 responses of 36% compared to 15% for placebo in the
anti-TNF-a experienced subpopulation (Ritchlin et al., 2014).
These data led to approval of ustekinumab use for PsA. Blocking
IL-17A with secukinumab for 24 weeks also showed good, and
perhaps as is the case for skin manifestation of psoriasis better,
efficacy in PsA with ACR20 and ACR50 response rates of 50%
and 35% compared to 17% and 7% for placebo (Mease et al.,
2015). Blocking multiple IL-17 isoforms for 12 weeks with broda-
lumab resulted in ACR20 andACR50 responses of 39%and14%
compared to 18% and 4% for placebo (Mease et al., 2014). Like
in RA, it appears that blocking multiple IL-17members (including
IL-17E) has less effect in the joint inflammation of PsA.
For AS, the only Th17 pathway inhibitor that has clinical results
in a double-blinded trial thus far is secukinumab, which in a small
Phase 2 study showed an ASAS20 (Sieper et al., 2009) response
rate of 59% compared to 24% for placebo (Baeten and Kuchroo,
2013). A Phase 3 studywith secukinumab has been completed in
AS, and results are pending. An open-label study with ustekinu-
mab also showed good results, but they are difficult to compare
due to study design and lack of a placebo arm (Poddubnyy et al.,
2014). Thus, the Th17 pathway in particular IL-17A is pathogenic
in both PsA and AS.
Non-infectious uveitis, like AS, is commonly associated with
HLAB27 and has overlapping mechanisms of pathogenesis. Af-
ter an early open-label study with high-dose 10 mg/Kg intrave-
nous secukinumab showed promising efficacy in active uveitis
(Hueber et al., 2010), three trials testing lower dose 300 mg sub-
cutaneous secukinumab in Behcet’s and non-Behcet’s, non-in-
fectious uveitis suggested beneficial effects of secukinumab but
there was no significant effect on the primary endpoints tested
(Dick et al., 2013). A subsequent study showed that higher doses
of secukinumab are required for efficacy in uveitis with clinical
response rates of 33% with 300mg SC, 62% with 10mg/Kg IV,
and 73% with 30mg/Kg IV (Letko et al., 2015), possibly due to
different levels of tissue distribution. These data are consistent
with the notion that dose and tissue distribution matter for a
pharmacodynamic effect in therapeutic intervention.
IL-17 has been implicated in contributing to asthma pathogen-
esis by its ability to attract neutrophils and eosinophils. Brodalu-
mab treatment for 12 weeks did not result in a significant effect
onmultiple parameters, butmight have had some effect in a sub-
set of patients whose disease was considered highly reversible
(Busse et al., 2013). Secukinumab has also been tested, but re-
sults are not yet available.Immunity 43, December 15, 2015 ª2015 Elsevier Inc. 1047
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dents, but the role of Th17 cells in multiple sclerosis has been
controversial. IL-17 was not considered to the pathogenic cyto-
kine in this disease model. IL-12+23 inhibitor ustekinumab
showed no efficacy in relapsing remitting multiple sclerosis
(RRMS) (Segal et al., 2008). The reason for this is not clear,
and it could be related to the doses used, which might not
have had adequate tissue exposure to fully suppress Th17 cells,
or the often opposite effects of Th1 and Th17 seen in EAE,
because IL-12+23 will inhibit generation of both these T cell sub-
sets. On the other hand, the IL-17A inhibitor secukinumab treat-
ment led to a decrease of the mean raw number of cumulative
unique active lesions (CCUAL) in patients with RRMS from
19.9 with placebo to 9.4 with secukinumab at 26 weeks, and
the mean raw number of cumulative new Gd-T1 lesions
decreased from 14.4 with placebo to 6.5 with secukinumab
(NCT01051817). Both CCUAL and Gd-T1 are measures of brain
and/or spinal cord inflammation as determined by magnetic
resonance imaging. Thus, IL-17A has a prominent role in the
pathogenesis of RRMS in man.
Concluding Remarks
Discovery of the Th17 cell and identification of its importance in
animal models of autoimmunity such as EAE, has led to an explo-
sion in the understanding of human immunology and autoimmu-
nity. Genetics and therapeutic interventions have provided the
biggest insights. Genome-wide association studies linked the
Th17 pathway by virtue of SNPs in the IL-23R to psoriasis,
Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and
ankylosing spondylitis. Identification of the genetic causes of pri-
mary immunodeficiency diseases, mostly by reverse genetics
testing Th17 pathway genes in immunodeficiency diseases
such as chronic mucocutaneous candidiasis, revealed that
Th17 cells have a critically important role in host immunity to
mucocutaneous candida infections and Staphylococcus aureus.
While defects in the entire Th17 pathway, IL-17RA/C, and its
signal transduction molecule Act1 lead to profoundly impaired
immunity and CMC, defects in IL-17F have a partial CMC pheno-
type indicating that IL-17A and IL-17F have overlapping and
redundant functions in immunity to Candida albicans. Therapeu-
tic interventions with inhibitors of IL-12+23, IL-23, IL-17A, and
IL-17RA all have variably beneficial effects in psoriatic skin
inflammation, with the Th17-specific therapies having dramati-
cally better efficacy than those that target both Th1 and Th17.
It is possible that Th1 and Th17 cells have counterregulatory
roles in psoriatic skin inflammation. Similarly, the IL-17A inhibitor
secukinumab has better efficacy than the IL-12+23 inhibitor us-
tekinumab in psoriatic joint inflammation. However, the IL-17RA
inhibitor brodalumab for reasons that are not yet clear but might
be due to concurrent inhibition of IL-17E, appears to be inferior to
IL-17A inhibitors in all types of joint inflammation tested thus far,
including rheumatoid arthritis and psoriatic arthritis. While IL-
12+23 inhibition has beneficial effects in Crohn’s disease, neither
IL-17A nor IL-17RA inhibitors are effective in this disease.
Whether this indicates an unlikely lack of Th17 involvement in
the disease or more likely a protective role for IL-17A remains
to be determined and will be informed by ongoing studies with
IL-23 inhibitors. As predicted by genetics and animal models,
Th17 pathway inhibition with IL-17A inhibitor secukinumab has1048 Immunity 43, December 15, 2015 ª2015 Elsevier Inc.excellent effects in HLA-B27 associated diseases ankylosing
spondylitis and uveitis. The role of Th17 and/or IL-17A in EAE
with extension to multiple sclerosis has been an area of contro-
versy, and data with secukinumab have shown that there is an
important role for IL-17A in multiple sclerosis. Therapeutic inhibi-
tion has confirmed the role of the Th17 pathway in immunity to
mucocutaneous Candida albicans with some patients contract-
ing mild to moderate candida infections localized to the skin
and mucosa that are easily treatable. These data also highlight
the fact that therapeutic interventions do not cause the same
level of immunodeficiency as a genetic defect. Thus, Th17 cells
play an important role in protective immunity against Candida
albicans and to a lesser degree Staphylococcus aureus and
are pathogenic in many autoimmune diseases. The different
components of the pathway each have unique characteristics
and variable involvement in protective and pathogenic immune
responses.AUTHOR CONTRIBUTIONS
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